TICKERNOMICS Sign up
Last Update: 2024-12-27 15:26:48
Acrivon Therapeutics Inc. ( ACRV ) https://www.acrivon.com
6.19USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
ACRV
24.30%
SPY
32.66%
ACRV
0.00%
SPY
108.59%
ACRV
0.00%
SPY
302.52%
ACRV
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
235.87
52.43
0.03
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-3.06
125.20
1.20
-24.31
0.00
-0.59
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-937.79
-11.89
-1173.45
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-157.08
-59.66
0.00
Other Earnings and Cash Flow Stats:
Acrivon Therapeutics Inc. ( ACRV ) Net Income TTM ($MM) is -76.98
Acrivon Therapeutics Inc. ( ACRV ) Operating Income TTM ($MM) is -85.30
Acrivon Therapeutics Inc. ( ACRV ) Owners' Earnings Annual ($MM) is 0.00
Acrivon Therapeutics Inc. ( ACRV ) Current Price to Owners' Earnings ratio is 0.00
Acrivon Therapeutics Inc. ( ACRV ) EBITDA TTM ($MM) is -84.45
Acrivon Therapeutics Inc. ( ACRV ) EBITDA Margin is -1173.45%
Capital Allocation:
Acrivon Therapeutics Inc. ( ACRV ) has paid 0.00 dividends per share and bought back -16.023969 million shares in the past 12 months
Acrivon Therapeutics Inc. ( ACRV ) has reduced its debt by 0.407 million USD in the last 12 months
Capital Structure:
Acrivon Therapeutics Inc. ( ACRV ) Interest-bearing Debt ($MM) as of last quarter is 4
Acrivon Therapeutics Inc. ( ACRV ) Annual Working Capital Investments ($MM) are 77
Acrivon Therapeutics Inc. ( ACRV ) Book Value ($MM) as of last quarter is 196
Acrivon Therapeutics Inc. ( ACRV ) Debt/Capital as of last quarter is 2%
Other Balance Sheet Stats:
Acrivon Therapeutics Inc. ( ACRV ) has 43 million in cash on hand as of last quarter
Acrivon Therapeutics Inc. ( ACRV ) has 14 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Acrivon Therapeutics Inc. ( ACRV ) has 38 common shares outstanding as of last quarter
Acrivon Therapeutics Inc. ( ACRV ) has 0 million USD of preferred stock value
Academic Scores:
Acrivon Therapeutics Inc. ( ACRV ) Altman Z-Score is 6.45 as of last quarter
Acrivon Therapeutics Inc. ( ACRV ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Acrivon Therapeutics Inc. ( ACRV ) largest shareholder is owning shares at 0.00 ($MM) value
EDELMAN JOSEPH(an insider) Bought 2353000 shares of Acrivon Therapeutics Inc. ( ACRV ) for the amount of $20000500.00 on 2024-04-11
22.39% of Acrivon Therapeutics Inc. ( ACRV ) is held by insiders, and 75.98% is held by institutions
Acrivon Therapeutics Inc. ( ACRV ) went public on 2022-11-15
Other Acrivon Therapeutics Inc. ( ACRV ) financial metrics:
FCF:-63.77
Unlevered Free Cash Flow:0.00
EPS:-2.36
Operating Margin:-937.79
Gross Profit Margin:-11.89
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-45.59
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Acrivon Therapeutics Inc. ( ACRV ) :
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.